VUNO's AI brain image analysis solution wins US health department's approval as medical device

SEOUL -- An artificial intelligence-based brain disease analysis solution created by South Korea's medical solution company VUNO was approved by the United States Food and Drug Administration as a medical device. The solution named "VUNO Med-DeepBrain" can help doctors identify degenerative brain diseases such as Alzheimer's disease and vascular dementia.

VUNO Med-DeepBrain divides brain magnetic resonance imaging (MRI) images into some 100 sections and provides information on brain atrophy. According to VUNO, the medical device can also be used to diagnose patients experiencing subjective cognitive decline (SCD), an early stage of dementia that worsens cognitive functioning. Memory loss is one of SCD's main symptoms.

VUNO said in a statement that the solution obtained approval from the U.S. FDA. Starting with the approval, the South Korean company aims to make a foray into the American market and partner with global pharmaceutical firms. "As the demand for early diagnosis has increased because of the emergence of next-generation dementia treatments, we will try hard to upgrade our sales capacity so that the product can be rapidly popularized in the U.S. market and help solve dementia problems," VUNO CEO Lee Ye-ha said in a statement on October 10.

South Korea has stepped up the development of AI-based robot doctors to efficiently analyze and diagnose the condition of patients based on medical records. In October 2021, South Korea's state research institute developed "Dr. AI," a robot doctor that can collect digitalized medical records and come up with diagnoses and predictions.

Kim Joo-heon jhkim123@ajunews.com

VUNO's AI brain image analysis solution wins US health department's approval as medical device

Related